Rosnilimab - AnaptysBio
Alternative Names: ANB-030Latest Information Update: 28 Dec 2023
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antibodies; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Programmed cell death 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia areata; Rheumatoid arthritis; Ulcerative colitis
- Phase I Autoimmune disorders
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (SC)
- 04 Dec 2023 Phase-II clinical trials in Ulcerative colitis in USA (SC) (NCT06127043)
- 27 Nov 2023 AnaptysBio plans a second global phase II ROSETTA trial in Ulcerative colitis in November 2023 (NCT06127043)